10-Q: Safety Shot Inc. Reports Q3 2024 Results, Navigates Rebranding and Legal Challenges

Safety Shot Inc. reported its Q3 2024 results, highlighting a period of rebranding and product transition alongside ongoing legal challenges and financial losses.

Summary

• Safety Shot Inc. reported a net loss of $11.9 million for the three months ended September 30, 2024, compared to a net loss of $7.7 million for the same period in 2023.
• The company's revenue increased to $110,213 in Q3 2024 from $11,877 in Q3 2023, primarily due to the launch of the Safety Shot dietary supplement.
• Operating expenses for Q3 2024 totaled $11.3 million, including significant marketing, legal, and stock-based compensation costs.
• The company experienced a gross loss of $292,186 in Q3 2024, due to high cost of sales of $402,399.
• For the nine months ended September 30, 2024, the net loss was $35.9 million, compared to a net loss of $9.4 million for the same period in 2023.
• The company's cash balance decreased to $1.36 million as of September 30, 2024, from $3.83 million at the end of 2023.
• A significant inventory write-down of $1.9 million was taken due to rebranding issues.
• The company is transitioning from a 12oz can to a 4oz shot and powder pack format.
• The company is facing multiple legal challenges, including lawsuits related to warrants and a delayed spin-off.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with significant losses, high expenses, and a declining cash balance. The company is also facing multiple legal challenges and operational issues. While there are some positive aspects, such as increased revenue and product development efforts, the overall sentiment is negative due to the significant risks and uncertainties.

Positives

• Revenue increased significantly in Q3 2024 compared to Q3 2023, indicating initial market traction for the Safety Shot product.
• The company is actively addressing product and branding issues by transitioning to new formats and rebranding.
• The company has secured a $500,000 loan agreement with Yerbae Brands Corp., potentially opening up synergistic opportunities.

Negatives

• The company experienced a substantial net loss of $11.9 million in Q3 2024 and $35.9 million for the nine months ended September 30, 2024.
• Operating expenses are very high, particularly in marketing, legal, and stock-based compensation.
• The company recorded a gross loss of $292,186 in Q3 2024.
• The company's cash balance has decreased significantly, raising concerns about its ability to continue as a going concern.
• The company is facing multiple legal challenges, which could result in significant costs and distractions.
• A significant inventory write-down of $1.9 million was necessary due to rebranding issues.

Risks

• The company's ability to continue as a going concern is in doubt due to accumulated deficits and cash flow used in operations.
• The company is facing multiple lawsuits, which could result in significant financial liabilities and reputational damage.
• The company's reliance on third-party manufacturers and suppliers poses risks to product quality and supply chain stability.
• The company's success depends on its ability to develop and maintain its brand and reputation, which could be harmed by negative publicity or product issues.
• The company's products are subject to government regulation, and unfavorable changes could substantially harm its business.
• The company's dependence on key personnel and the potential for turnover could harm its business.
• The company's products may not meet health and safety standards or could become contaminated, leading to recalls and liability claims.
• The company's ability to compete effectively depends on its ability to create and expand brand awareness.
• The company's success depends on its ability to develop and introduce new products, which is subject to various risks.
• The company's clinical trials may be delayed or terminated, which could harm its product development efforts.
• The company may not be able to establish relationships with licensees or collaborators to carry out sales, marketing, and distribution functions.
• The company's operations are subject to interruption by natural disasters, fire, power shortages, pandemics and other events beyond its control.
• The company has a limited operating history upon which investors can evaluate its future prospects.
• The company's products and manufacturing activities are subject to extensive government regulation, and failure to comply with these laws and regulations may increase its costs.
• The company's reliance on third parties to conduct clinical trials and most nonclinical studies of its products poses risks to its product development and commercialization efforts.
• The company may not meet its product development and commercialization milestones.
• The company's operations in international markets involve inherent risks that it may not be able to control.
• The company's compliance with new and existing laws and governmental regulations could increase its costs significantly and adversely affect its results of operations.
• The company's reliance on third parties to manufacture and supply its products may harm its business, financial condition and operating results.
• The company's intellectual property rights may not be adequately protected, which could reduce the value of its products and brands.
• The company's accountant has indicated doubt about its ability to continue as a going concern.
• The company may need to raise additional capital, which could cause dilution to its existing stockholders.
• The company's management has limited experience in managing the day-to-day operations of a public company.
• The company's common stock may become subject to the SEC's penny stock rules, which could adversely affect trading activity.
• The company's Second Amended and Restated Certificate of Incorporation contains an exclusive forum provision for certain claims, which could limit its stockholders' ability to obtain a favorable judicial forum for disputes.
• The company's issuance of additional common stock or preferred stock may cause its common stock price to decline.
• Anti-takeover provisions in the company's charter and bylaws may prevent or frustrate attempts by stockholders to change the board of directors or current management.

Future Outlook

The company plans to continue developing new flavors and dosages for its products, conduct research studies, and expand its distribution network. The company is also focused on transitioning to a 4oz product and powder packs.

Management Comments

• The first 3 quarters since Sure Shot was launched was our opportunity to test, learn, iterate, and evolve our branding and product.
• This period has helped us to better understand our target consumers, what they want, and how we can better meet their needs.
• We have gathered these learnings, we have gained valuable insights that have allowed us to shape our strategy for sustainable long-term growth and success.
• We made the decision to do a brand refresh as well as transition into a 4oz product and powder packs.
• This transitional period occurred during Q3 as we felt this was the best time to make the change as we head into a big 2025 year.

Industry Context

The company operates in the competitive wellness and dietary supplement market, facing challenges from established brands and new entrants. The company's focus on a unique product with clinical backing is an attempt to differentiate itself in this market. The company is also navigating increasing regulatory scrutiny and legal challenges common in this industry.

Comparison to Industry Standards

• The company's significant net losses and high operating expenses are concerning when compared to established players in the dietary supplement industry, which typically aim for profitability and efficient operations.
• The company's gross loss indicates that its cost of goods sold is higher than its revenue, which is not sustainable in the long term and is not typical of established companies in the industry.
• The company's cash burn rate is high, and its cash balance is low, which is a significant concern compared to industry standards where companies typically maintain a healthy cash position.
• The company's involvement in multiple legal proceedings is unusual for a company of its size and stage, and it is a significant risk compared to industry benchmarks.
• The company's inventory write-down due to rebranding issues is a sign of operational challenges and is not typical of well-managed companies in the industry.
• The company's transition to a new product format is a strategic move, but it also introduces risks and uncertainties, which is not typical of established companies that have a stable product line.
• The company's reliance on third-party manufacturers and suppliers is common in the industry, but the company's ability to manage these relationships effectively is crucial for its success.
• The company's focus on clinical trials and scientific backing is a positive differentiator, but it also adds to its costs and risks compared to companies that do not invest in such research.

Legal Proceedings

• The company is involved in multiple legal proceedings, including lawsuits from Intracoastal Capital, Sabby Volatility Warrant Master Fund, 3i LP, Bigger Capital fund, and Alta Partners.
• These lawsuits relate to warrants, a delayed spin-off, and other contractual disputes.
• The company intends to vigorously defend itself against these claims.

Stakeholder Impact

• Shareholders are negatively impacted by the company's significant losses and declining cash balance.
• Employees may be affected by the company's financial instability and potential restructuring.
• Customers may be affected by the company's product transition and potential supply chain disruptions.
• Suppliers may be affected by the company's financial instability and potential payment delays.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company plans to continue developing new flavors and dosages for its products.
• The company plans to conduct research studies to support product development.
• The company plans to expand its distribution network.
• The company is focused on transitioning to a 4oz product and powder packs.

Key Dates

Keywords

Safety Shot, dietary supplement, blood alcohol content, rebranding, legal proceedings, financial results, operating expenses, net loss, clinical trials, intellectual property, warrants, convertible notes, stock compensation, going concern